Equities Analysts Set Expectations for Agile Therapeutics Inc’s FY2022 Earnings (NASDAQ:AGRX)

Equities Analysts Set Expectations for Agile Therapeutics Inc’s FY2022 Earnings (NASDAQ:AGRX)

Agile Therapeutics Inc (NASDAQ:AGRX) – Equities researchers at Oppenheimer lowered their FY2022 earnings per share (EPS) estimates for shares of Agile Therapeutics in a research report issued on Monday, August 5th. Oppenheimer analyst L. Gershell now expects that the specialty pharmaceutical company will post earnings of $1.34 per share for the year, down from their prior forecast of $1.38. Oppenheimer has a “Outperform” rating and a $5.00 price target on the stock. Oppenheimer also issued estimates for Agile Therapeutics’ FY2023 earnings at $1.71 EPS.

AGRX has been the topic of several other reports. Janney Montgomery Scott assumed coverage on shares of Agile Therapeutics in a research note on Friday, April 12th. They issued a “buy” rating and a $4.00 target price on the stock. ValuEngine cut shares of Agile Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, August 1st. Zacks Investment Research upgraded shares of Agile Therapeutics from a “hold” rating to a “strong-buy” rating and set a $1.25 target price on the stock in a research note on Tuesday. Finally, Maxim Group set a $3.00 target price on shares of Agile Therapeutics and gave the stock a “buy” rating in a research note on Monday, June 10th. One equities research analyst has rated the stock with a sell rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $3.45.

NASDAQ AGRX opened at $1.06 on Wednesday. Agile Therapeutics has a 1 year low of $0.23 and a 1 year high of $1.70. The stock has a market cap of $44.55 million, a PE ratio of -1.83 and a beta of 0.54. The business has a 50 day moving average price of $1.34.

Agile Therapeutics (NASDAQ:AGRX) last posted its earnings results on Thursday, August 1st. The specialty pharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.11) by $0.03.

Several large investors have recently modified their holdings of AGRX. Acadian Asset Management LLC increased its holdings in shares of Agile Therapeutics by 33.3% in the 1st quarter. Acadian Asset Management LLC now owns 417,269 shares of the specialty pharmaceutical company’s stock worth $630,000 after buying an additional 104,222 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Agile Therapeutics by 24.0% in the 4th quarter. Geode Capital Management LLC now owns 230,496 shares of the specialty pharmaceutical company’s stock worth $132,000 after buying an additional 44,639 shares during the last quarter. Finally, BlackRock Inc. grew its holdings in shares of Agile Therapeutics by 15.7% during the 4th quarter. BlackRock Inc. now owns 133,219 shares of the specialty pharmaceutical company’s stock valued at $77,000 after purchasing an additional 18,038 shares during the last quarter. 42.38% of the stock is currently owned by hedge funds and other institutional investors.

In related news, CEO Alfred Altomari purchased 20,000 shares of the firm’s stock in a transaction dated Monday, June 10th. The shares were purchased at an average price of $1.27 per share, with a total value of $25,400.00. Following the acquisition, the chief executive officer now directly owns 258,568 shares of the company’s stock, valued at $328,381.36. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. 8.50% of the stock is owned by corporate insiders.

About Agile Therapeutics

Agile Therapeutics, Inc, a women’s healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch, which completed Phase III clinical trials.

Share:
Scroll Up